Personalized medicine: current status and prospects

Home/2019, Vol. 7, No. 1/Personalized medicine: current status and prospects

Cell and Organ Transplantology. 2019; 7(1):63-65.
DOI: 10.22494/cot.v7i1.96

Personalized medicine: current status and prospects

Nasadyuk C., Sklyarov O.
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

The article presents modern view at the personalized (precision) medicine and discusses the role of genome, glycobiome, microbiome studies in the selection of individualized treatment. Actual data on the options of target immunotherapy of cancer are presented. Up-to-date feasibility of personalized therapy and perspectives for its development are considered.

Key words: personalized medicine; precision medicine; genome; glycobiome; microbiome

Full Text PDF (eng) Full Text PDF (ua)

1. Almeida A, Kolarich D. The promise of protein glycosylation for personalized medicine. Biochim Biophys Acta. 2016; 1860(8):1583-1595.
2. Miura Y, Endo T. Glycomics and glycoproteomics focused on aging and age-related diseases-Glycans as a potential biomarker for physiological alterations. Biochim Biophys Acta. 2016; 1860(8):1608-1614.
3. Baxendale S, van Eeden F, Wilkinson R. The Power of Zebrafish in Personalized Medicine. Adv Exp Med Biol. 2017; 1007:179-197.
4. Balfour-Lynn IM. Personalized medicine in cystic fibrosis is unaffordable. Paediatr Respir Rev. 2014; 15(1):2-5.
5. Savard J. Personalized medicine: a critique on the future of health care. J Bioeth Inq.2013; 10(2):197-203.
6. Brittain HK, Scott R, Thomas E. The rise of the genome and personalized medicine. Clinical Medicine. 2017; 17(6): 545-551.
PMid:29196356 PMCid:PMC6297695
7. Dalbeth N, Stamp LK, Merriman TR. The genetics of gout: towards personalized medicine? BMC Medicine. 2017; 15:108.
PMid:28566086 PMCid:PMC5452604
8. Hov JE, Trøseid M. Personalized medicine targeting the gut microbiota? Tidsskr Nor Laegeforen. 2015; 135(7):624.
9. Day S, Coombes RC, McGrath-Lone L, et al. Stratified, precision or personalized medicine? Cancer services in the ‘real world’ of a London hospital. Sociol Health Illn. 2017; 39(1):143-158.
10. Arjmand B, Goodarzi P, Mohamadi-Jahani F. Personalized Regenerative Medicine. Acta Medica Iranica. 2017; 55(3):144-149.
11. Krasnewich D. Human glycosylation disorders. Cancer Biomarkers. 2014; 14:3-16.
12. Schnaar RL. Glycobiology simplified: diverse roles of glycan recognition in inflammation. Journal of Leukocyte Biology. 2016; 99(6):825-838.
PMid:27004978 PMCid:PMC4952015
13. Adkar SS, Brunger GM, Willard VP, et al. Genome Engineering for Personalized Arthritis Therapeutics. Trends Mol Med. 2017; 23(10): 917-931.
PMid:28887050 PMCid:PMC5657581
14. Kavanaugh D, O’Callaghan J, Kilcoyne M. The intestinal glycome and its modulation by diet and nutrition. Nutrition Reviews. 2015; 73(6):359-375.
15. Zenner HP. Individual Biomarkers Using Molecular Personalized Medicine Approaches. ORL J Otorhinolaryngol Relat Spec. 2017; 79(1-2):7-13.
16. Shukla SK, Murali NS, Brilliant MH. Personalized Medicine Going Precise: From Genomics to Microbiomics. Trends Mol Med. 2015; 21(8):461-462.
PMid:26129865 PMCid:PMC4530069
17. Hartmann J. Clinical development of CAR T cells – challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017; 9(9):1183-1197.
PMid:28765140 PMCid:PMC5582407
18. Ren J, Zhao Y. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. Protein Cell. 2017; 8(9):634-643.
PMid:28434148 PMCid:PMC5563282
20. Jackson SE, Chester JD. Personalized cancer medicine. Int J Cancer. 2015; 137:262-266.
21. Marotz CA, Zarrinpar A. Treating Obesity and Metabolic Syndrome with Fecal Microbiota Transplantation. Yale J Biol Med. 2016; 89(3):383-388.
22. Gilbert B, Schrenzel J. Fecal microbiota transplantation: current status and prospect. Rev Med Suisse. 2019; 15(650):976-983.
23. Chang CS, Ruan JW, Kao CY. An overview of microbiome based strategies on anti-obesity. Kaohsiung J Med Sci. 2019; 35(1):7-16.
24. Tavassoly I, Hu Y, Zhao S, et al. Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses. Mol Oncol. 2019. DOI: 10.1002/1878-0261.12521. [Epub ahead of print].
25. El-Deiry WS, Goldberg RM, Lenz HJ, et al. The current state of molecular testing in the treatment of patients with solid tumors. CA Cancer J Clin. 2019. DOI: 10.3322/caac.21560. [Epub ahead of print].

Nasadyuk C, Sklyarov O. Personalized medicine: current status and prospects. Cell and Organ Transplantology. 2019; 7(1):63-65. doi:10.22494/cot.v7i1.96

Creative Commons License
Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.